Zydus Lifesciences launches Semaglutide Injection

21 Mar 2026 Evaluate

Zydus Lifesciences has launched Semaglutide Injection under the brand names - SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.

Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, the company offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost. The company’s Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at the company’s Biotech Park, Ahmedabad. The average monthly cost of the treatment will be around Rs 2,200.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

890.60 14.25 (1.63%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×